UK biotech company Kymab is to collaborate with China’s EpimAb Biotherapeutics to develop bispecific ... In-Tandem Immunoglobulin (FIT-Ig) platform to generate multiple bispecific antibodies.

Study: Bispecific antibodies with broad neutralization ... bispecific, and tandem single-chain fragment variable (scFv) bispecific formats. Each developed bsAbs was then cloned into an AbVec2.1 ...

The bispecific BCMA-CD19 CAR-T cells containing anti-BCMA single chain variable fragment (scFv) and anti-CD19 scFv in tandem, linked by GGGGS×4, could cover almost all stages of the B-cell ...

Bispecific antibodies (bsAbs) represent a significant advancement in ... to overcoming unique challenges across diverse formats like CrossMab, ScFv-Fab, and more. By leveraging innovative approaches, ...

Shanghai-based VelaVigo has been busy. The biotech granted Avenzo Therapeutics ex-China rights to a Nectin4xTROP2 bispecific antibody-drug conjugate in November, netting up to $50 million in ...

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug. The two companies ...